The Goldman Sachs technology M&A team, led by Sam Britton, has cashed in on its software focus and decades of experience to dominate 2019's biggest deals.Technologyread more
American small and medium-size companies that rely on China are scrambling to adjust their business plans in response to the escalating trade war.Traderead more
Here are the products that stand to be the most affected by China's new tariffs on $75 billion worth of U.S. goods.Marketsread more
The summit comes amid fears over a global economic slowdown, and U.S. tensions over trade allies, Iran and Russia.Politicsread more
The world's second biggest economy is past a point where it cannot ignore its enormous debt anymore, according to an analyst.China Economyread more
Carl Medlock used to work at Tesla. Now he's one of the few people in the U.S. that can fix the company's original Roadster electric vehicles.Technologyread more
Trump does have some powerful tools that would not require approval from U.S. Congress.Politicsread more
Stocks dropped after Donald Trump ordered that U.S. manufacturers find alternatives to their operations in China.US Marketsread more
As demand for lab monkeys continues to rise, U.S. scientists are reporting delays in research projects because they can't obtain enough animals, according to the National...Politicsread more
The European Union will respond in kind if the U.S. imposes tariffs on France over digital tax plan, EU chief Donald Tusk told G-7.Technologyread more
Trump said he will raise tariffs on $250 billion in Chinese goods to 30% and hike duties on another $300 billion in products to 15%.Politicsread more
Johnson & Johnson on Tuesday reported quarterly earnings that beat Wall Street expectations, despite a 7.2 percent drag on the strong dollar.
The diversified health care giant also lowered 2015 financial guidance due to further negative foreign currency movements.
"People can figure out what the move in the currency has been, and we're fairly used to this. This was already factored in to expectations. So you see now impact from the lower guidance," Barbara Ryan, partner at strategic adviser Clermont Partners, said shortly after the release. "They lowered guidance back in January because of the rise in the dollar. But it's gotten worse."
J&J posted first quarter earnings of $1.56 per share, up from $1.54 a share in the year-earlier period. Revenue dropped to $17.4 billion from $18.1 billion a year ago.
Analysts expected earnings of $1.54 per share on revenue of $17.31 billion.
After the announcement. J&J's stock rose in premarket trading. (Click here for the latest price.)
Year to date, Johnson & Johnson has underperformed the broader S&P 500 pharmaceutical industry. While the group has risen 5 percent year, J&J was down more than 3 percent in 2015.
"A lot of the outperformance has been drive by multiple expansion," said Ryan, who specializes in health care and life sciences.
She predicted that investors will be much more focused on individual product portfolios. While J&J has been strong in pharma, she added, there are concerns about increased competition from rivals.